DongKoo Bio & Pharma Co. Ltd. Total Liabilities
DongKoo Bio & Pharma Co. Ltd. total liabilities. Based on the latest financial reports, DongKoo Bio & Pharma Co. Ltd. (006620) has total liabilities worth ₩176.02 Billion KRW (≈ $119.29 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 006620 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of DongKoo Bio & Pharma Co. Ltd. (2015–2025)
Total liabilities of DongKoo Bio & Pharma Co. Ltd. from 2015 to 2025. This chart illustrates how DongKoo Bio & Pharma Co. Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore DongKoo Bio & Pharma Co. Ltd. long-term investment intensity to see how much of total assets are deployed in long-term investments.
DongKoo Bio & Pharma Co. Ltd. Competitors by Total Liabilities
The table below lists competitors of DongKoo Bio & Pharma Co. Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Slj Global Tbk
JK:SULI
|
Indonesia | Rp486.05 Billion |
|
Kidoz Inc
V:KIDZ
|
Canada | CA$2.19 Million |
|
Nextplat Corp
NASDAQ:NXPL
|
USA | $12.19 Million |
|
Rackla Metals Inc
V:RAK
|
Canada | CA$1.31 Million |
|
Bull Will Co Ltd
TWO:6259
|
Taiwan | NT$178.69 Million |
|
Daebo Magnetic Co.Ltd
KQ:290670
|
Korea | ₩29.68 Billion |
|
Protasco Bhd
KLSE:5070
|
Malaysia | RM529.18 Million |
|
Agroton Public Ltd.
WAR:AGT
|
Poland | zł2.76 Million |
Liability Composition Analysis (2015–2025)
This chart breaks down DongKoo Bio & Pharma Co. Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see DongKoo Bio & Pharma Co. Ltd. total assets.
Liquidity & Leverage Metrics
DongKoo Bio & Pharma Co. Ltd. Total Liabilities Ratios Explained
DongKoo Bio & Pharma Co. Ltd. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.90 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.55 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how DongKoo Bio & Pharma Co. Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for DongKoo Bio & Pharma Co. Ltd. (2015–2025)
The table below shows the annual total liabilities of DongKoo Bio & Pharma Co. Ltd. from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩184.19 Billion ≈ $124.82 Million |
+32.77% |
| 2024-12-31 | ₩138.73 Billion ≈ $94.01 Million |
+72.00% |
| 2023-12-31 | ₩80.66 Billion ≈ $54.66 Million |
+15.30% |
| 2022-12-31 | ₩69.95 Billion ≈ $47.41 Million |
+27.97% |
| 2021-12-31 | ₩54.66 Billion ≈ $37.04 Million |
+9.98% |
| 2020-12-31 | ₩49.70 Billion ≈ $33.68 Million |
+5.58% |
| 2019-12-31 | ₩47.07 Billion ≈ $31.90 Million |
+46.28% |
| 2018-12-31 | ₩32.18 Billion ≈ $21.81 Million |
-14.97% |
| 2017-12-31 | ₩37.85 Billion ≈ $25.65 Million |
-12.52% |
| 2016-12-31 | ₩43.27 Billion ≈ $29.32 Million |
-25.69% |
| 2015-12-31 | ₩58.22 Billion ≈ $39.46 Million |
-- |
About DongKoo Bio & Pharma Co. Ltd.
DongKoo Bio&Pharma. Co., Ltd. researches, develops, manufactures, and sells medicines in South Korea. The company offers prescribed medicines, such as liver disease, skeletal muscle relaxant, endocrine system, brain nervous system, urogenital, antiobestic, digestive system, circulatory organ, allergenic, mental disease, oral dermatology, external preparation of dermatology, antiseptic, antiviral,… Read more